Methylene blue is an old synthetic dye that donates electrons in the mitochondrial transport chain at low doses and inhibits MAO at high doses. It is FDA-approved for methemoglobinemia, and recent randomized trials show a pressor-sparing benefit in septic shock without proven mortality benefit. For cognition, two small fMRI trials show acute effects but no chronic-dosing trial exists, and the phase 3 Alzheimer's program is contested because it lacked a true placebo arm.
Summary drafted from this entry’s sources; editorial review pending.
01Key questions
What is methylene blue used for?
Approved uses are methemoglobinemia, ifosfamide encephalopathy and diagnostic dyeing. Off-label interest covers cognition, mitochondrial support and septic shock.
Does methylene blue improve cognition?
Acutely, maybe: two small double-blind fMRI trials found improved memory retrieval and altered network activity after a single low dose. Chronic cognitive enhancement has never been tested in a randomized trial.27
Does methylene blue work for Alzheimer's?
The LUCIDITY phase 3 reported sustained cognitive benefit and reduced neurodegeneration markers, but the comparator was an active low dose rather than placebo, earlier phase 3 trials failed overall, and independent experts remain skeptical.5
Is methylene blue safe?
Pharmaceutical-grade MB is well tolerated at studied doses in adults without G6PD deficiency. The dominant risks are serotonin syndrome with serotonergic drugs and hemolysis in G6PD deficiency; industrial dye is unsafe to ingest.
What would change this rating?
A chronic-dosing randomized trial for cognitive enhancement and a true placebo-controlled Alzheimer's trial.
Core thesis: Methylene blue is experiencing a renaissance in biohacking and functional medicine. At low doses (0.5-4 mg/kg), it acts as a mitochondrial electron donor, bypassing damaged complexes and boosting ATP. At high doses, it inhibits MAO enzymes. 2023–2026 transformed the evidence landscape: the TauRx Phase 3 LUCIDITY program published in full (March 2026), a wave of septic-shock RCTs and meta-analyses landed, and human fMRI studies mapped its acute cognitive effects. Its unique pharmacology offers potential for cognitive enhancement, mitochondrial optimization, antimicrobial and vasoplegic applications — but dosing must be precise.
02History and Background
Medical Origins
- 1856: First synthesized as a textile dye
- 1891: First used as an anti-malarial
- 1930s-40s: Used for methemoglobinemia (FDA-approved use)
- 1980s-90s: Research on MAO inhibition and neuroprotection
- 2010s-present: Biohacking renaissance for mitochondrial/cognitive applications
- 2023-2026: Critical-care revival (septic shock RCTs) and full Phase 3 publication of the tau aggregation inhibitor program
Current FDA-Approved Uses
- Methemoglobinemia: Converts methemoglobin to hemoglobin (IV methylene blue)
- Ifosfamide-induced encephalopathy: Adjunct treatment
- Urinary tract diagnostics: Dye for certain procedures
03Mechanism of Action
Uses
Uses
- Primary action: Electron donor in mitochondrial electron transport chain
- Mechanism: Bypasses Complex I; donates electrons directly to cytochrome c
- Effects:
- Increased ATP production
- Reduced oxidative stress (iron oxidation vs. normal ROS production)
- Enhanced mitochondrial efficiency
- Neuroprotection
Uses
- Primary action: MAO-A and MAO-B inhibition
- Mechanism: Irreversible monoamine oxidase inhibition
- Effects:
- Increased dopamine, norepinephrine, serotonin
- Potential for tyramine interactions (cheese effect)
- More pronounced CNS effects
- Note: Not typically used in biohacking due to side effect profile
Additional Mechanisms (relevant to newer evidence)
- Tau aggregation inhibition: Methylthioninium inhibits aggregation of tau filaments — basis of the TauRx program (see Alzheimer's section)
- iNOS / soluble guanylate cyclase inhibition: Blocks nitric oxide-mediated vasodilation — basis of the vasoplegic-shock indications
- Proteasome activation: Reduces Aβ levels via increased proteasomal degradation (Medina et al. 2011, PMID 20731659)
Key Molecular Interactions
| Target | Low Dose Effect | High Dose Effect |
|---|---|---|
| Complex I | Bypasses (electron donor) | Inhibited |
| Complex IV | May increase activity | May inhibit |
| Cytochrome c | Direct electron donation | Variable |
| MAO-A/B | Minimal inhibition | Strong inhibition |
| Nitric oxide | Reduces NO production | Variable |
| Tau filaments | Aggregation inhibition | Aggregation inhibition |
Swipe table →
04Doses in studies
Cognitive Enhancement / Mitochondrial Optimization
Uses
- Monitoring: Essential; watch for side effects
Weight-Based Quick Reference
| Body Weight | Standard (2 mg/kg) |
|---|---|
| 70 kg (154 lbs) | 140 mg |
| 80 kg (176 lbs) | 160 mg |
| 90 kg (198 lbs) | 180 mg |
| 100 kg (220 lbs) | 200 mg |
Swipe table →
Administration
- Oral: Most common; 1% solution under tongue or mixed
- Sublingual: Faster absorption, bypasses first-pass
- IV: Medical setting only; for methemoglobinemia or vasoplegia
05Form and Purity
What to Look For
- USP pharmaceutical grade — critical for purity
- 1% solution in amber glass bottles (light-sensitive)
- No fillers or additives
- From reputable supplier (e.g., Sigma-Aldrich, lab-grade)
Red Flags
- Industrial dye grade (not for internal use)
- Powder form (difficult to dose accurately)
- Unknown supplier / no purity testing
Note on Color
- Pure methylene blue turns urine blue/green (normal)
- Can stain mouth/teeth temporarily
- Staining is harmless
06Applications and Evidence
1. Cognitive Enhancement — Human Neuroimaging Evidence
Evidence grade: moderate (replicated acute-dose RCTs in healthy adults, mechanistic fMRI; no chronic-dosing RCTs for enhancement)
Two double-blind, placebo-controlled fMRI trials from UT Austin (Rodriguez et al.) form the core human evidence:
- Radiology 2016 (PMID 27351678): 26 healthy subjects (22–62 y), randomized crossover, single low oral dose (~280 mg) 1 h before scanning. MB increased fMRI activity in bilateral insular cortex during sustained attention and in the parietal/occipital network during short-term memory tasks, and potentiated memory retrieval on a delayed match-to-sample task (~7% improvement vs placebo).
- PNAS 2017 (PMID 26961091): Same design; MB increased resting-state functional connectivity between perception and memory networks (insula, parahippocampal, amygdala regions) and reduced task-related cerebral blood flow — consistent with improved oxidative efficiency rather than simple vasodilation.
- Ongoing: NCT02380573 (Univ. of Texas) tests 2-week and 12-week USP MB dosing with fMRI in healthy aging, MCI, and mild AD — results pending publication.
Bottom line: acute low-dose MB measurably alters human brain network function in controlled settings. Chronic enhancement claims remain untested in RCTs.
2. Alzheimer's Disease — TauRx / Hydromethylthionine Program (updated 2026-08)
Evidence grade: contested Phase 3 — positive company-reported results without a true placebo arm
LUCIDITY Phase 3 (NCT03446001) — 12-month double-blind (HMTM 16 mg/day vs low-dose methylthioninium chloride 4 mg twice-weekly as active placebo) + 12-month open-label extension; full publication J Prev Alzheimers Dis 2026;13(3):100480: - Cognitive improvement over baseline sustained 78 weeks in the early-start MCI group; no significant cognitive or functional decline to 104 weeks - Reduced neurodegeneration: plasma NfL change significantly lower at 52 weeks (p = 0.0291); grey-matter atrophy progression reduced at 52 and 104 weeks - Reduced tau pathology: pTau217 progression reduced in MCI (p = 0.0165) - Safety: headache 1.5%, diarrhea 1.2% — benign profile
AD/PD 2025 (Vienna) propensity-matched analysis: vs external matched placebo from the CPAD database, HMTM 16 mg/day showed an 82% reduction in cognitive decline (ADAS-cog13) at 18 months (115% in early AD), 35% reduction in whole-brain atrophy; CDR global same-or-better at 2 years: 71% vs 52%.
Critical caveats (why the field hasn't embraced it): - No true placebo arm — the comparator was low-dose MTC (biologically active). Analyses lean on external/historical matched controls (ADNI, CPAD propensity matching). - Prior Phase 3 LMTX trials (2016) failed overall; benefit appeared only in the monotherapy subgroup not taking AChEIs/memantine — the basis of the monotherapy hypothesis LUCIDITY was designed around. - Preclinical interaction: chronic AChE-inhibitor pretreatment blocks HMTM's cholinergic/mitochondrial/synaptic effects in mice (Kondak 2023; Schwab 2024; Zadrozny 2024) — mechanistically coherent with the monotherapy claim, but also a convenient post-hoc story. - Independent leaders remain skeptical: at Tau Global 2025, Adam Boxer called tau aggregation inhibitors effectively a "nonstarter" with unclear mechanism. - Preclinical tau-transgenic work (Hochgräfe et al., see Alzforum coverage) suggests methylthioninium works best prophylactically/early — after substantial pathology, the therapeutic window may close.
3. Mitochondrial Optimization
- Evidence: Strong molecular/mechanistic; emerging human data
- Mechanism: Electron donation bypassing damaged Complex I
- Applications: Fatigue, age-related decline, athletic performance
- Note: Most compelling application for biohacking
4. Septic and Vasoplegic Shock (new section 2026-08)
Evidence grade: multiple RCTs + meta-analyses; consistent hemodynamic benefit, mortality benefit unproven
MB inhibits inducible NO synthase and soluble guanylate cyclase, restoring vascular tone in catecholamine-refractory vasoplegia. The 2023–2025 RCT wave:
- Ibarra-Estrada et al., Crit Care 2023;27:110: early adjunctive MB (within 24 h of septic-shock diagnosis) reduced time to vasopressor discontinuation, cumulative fluid balance, and ICU/hospital length of stay vs placebo; no severe adverse effects.
- Meta-analysis (J Clin Med 2026;15(12):4481): 9 RCTs, 535 patients — no statistically significant short-term mortality reduction; hemodynamic/pressor-sparing effects consistent.
Bottom line: MB is moving from "rescue therapy" to early adjunct in ICU practice for pressor-sparing, but outcome-level benefit is not yet established.
5. Mood Support
- Evidence: Limited but interesting
- Mechanism: MAO inhibition at higher doses; mitochondrial support at lower
- Reports: Some users report improved mood, motivation
- Caution: Requires careful dosing; not first-line treatment
6. Anti-Microbial / Anti-Parasitic
- Evidence: Historical and emerging
- Applications: Malaria (historical), resistant bacteria, parasites
- Mechanism: Interference with electron transport in pathogens
- Note: Not first-line treatment in modern medicine
7. Skin / Topical
- Evidence: Anecdotal
- Applications: Wound healing, skin conditions
- Use: Diluted solution applied topically
07Combinations Discussed in the Literature
Synergistic Combinations
| Stack | Rationale |
|---|---|
| Methylene blue + Red light therapy | Complementary mitochondrial support (photobiomodulation + electron shuttle) |
| Methylene blue + CoQ10 | Multiple points in electron transport chain |
| Methylene blue + PQQ | Mitochondrial biogenesis + function |
| Methylene blue + B-complex | Energy metabolism support |
Swipe table →
Caution
- Do not stack with: Other MAO inhibitors, high-dose SSRIs, serotonergic compounds (serotonin syndrome risk at higher doses)
- Do not combine with acetylcholinesterase inhibitors when targeting tau/long-term cognitive endpoints — preclinical evidence shows AChEIs blunt HMTM's effects (see Alzheimer's section)
- Studies started low: Always begin with lowest dose to assess tolerance
08Contraindications and Cautions
Do NOT Use If
- G6PD deficiency — risk of hemolytic anemia
- Pregnancy/breastfeeding — insufficient safety data
- Methemoglobinemia (taking conventional treatment) — contraindicated
- On MAO inhibitors — dangerous interaction
- On serotonergic medications — risk of serotonin syndrome at higher doses
Cautions
- Studies started low: 0.25-0.5 mg/kg to assess tolerance
- Stay hydrated: Can cause dry mouth
- May stain: Urine, clothing
- Photosensitivity: Avoid excessive sun exposure
- Kidney/liver disease: Use under supervision
- CNS effects: Clinical-trial reports include confusion, dizziness, and visual disturbance — avoid driving until effects are known (StatPearls, updated Jan 2026)
Approaches Reported in the Literature
- Nausea, GI upset
- Headache
- Blue/green urine (normal)
- Staining of mouth/teeth (temporary)
- Anxiety/jitteriness
- High doses: hypotension, cardiac effects, hemolysis in G6PD deficiency
09Doses in studies
The Hormetic Window
Methylene blue exhibits hormesis — opposite effects at low vs. high doses. The therapeutic window is narrow:
| Primary Effect | Risk Level |
|---|---|
| Mitochondrial electron donation | Low |
| Optimal cognitive/mitochondrial effects | Moderate |
| MAO inhibition begins | Elevated |
| Significant MAO-A/B inhibition, side effects | High |
Swipe table →
⚠️ Above 7–10 mg/kg, risks increase substantially. Most biohacking applications stay at 0.5–2 mg/kg.
Uses
Goal: Minimize side effects while testing individual response
| Parameter | Value |
|---|---|
| Form | 1% USP solution, oral or sublingual |
Swipe table →
Start here. Do not advance until you assess tolerance.
Uses
Goal: Therapeutic mitochondrial and cognitive effects
| Parameter | Value |
|---|---|
| Duration | — |
| Form | 1% USP solution |
| — | — |
Swipe table →
Uses
Goal: Maximum mitochondrial boost, short duration only
| Parameter | Value |
|---|---|
| Monitoring | Required — track side effects |
| Form | 1% USP solution |
Swipe table →
Not recommended without physician supervision.
Oral Solution (1% USP)
The standard form for biohacking use:
- 1% solution = 10 mg/mL
- Store in amber glass bottle (light-sensitive)
- Can be taken sublingually (faster absorption) or mixed with water/juice
Uses
- Drop under tongue, hold 60–90 seconds before swallowing
- Pros: Faster onset, bypasses first-pass hepatic metabolism
- Cons: Strong taste, potential mouth staining
IV Administration
- Medical setting only
- Used for methemoglobinemia, vasoplegic shock, ifosfamide encephalopathy
- Not appropriate for biohacking/self-experimentation
Baseline Assessments (Before Use)
- G6PD testing — required before first use (risk of hemolytic anemia if deficient)
- Liver function — MB is hepatically metabolized
- Kidney function — excreted renally
- Medication review — identify serotonergic and MAOI interactions
Monitoring Parameters
| Parameter | Frequency | Notes |
|---|---|---|
| Blood pressure | Baseline, week 1, week 4 | MB can cause hypotension at higher doses |
| Mood/anxiety | Weekly | Watch for anxiety, jitteriness |
| Sleep quality | Weekly | Studies administered morning only; avoid late doses |
| GI symptoms | As needed | Nausea is common at higher doses |
| Urine color | Always | Blue/green = normal; dark = stay hydrated |
Swipe table →
Absolute Contraindications
- G6PD deficiency — high risk of hemolytic anemia
- Pregnancy / breastfeeding — insufficient safety data
- Active methemoglobinemia — conventional treatment in progress
- Concurrent MAO inhibitor use — risk of hypertensive crisis
Relative Contraindications / Use with Caution
- Tricyclic antidepressants — potential interaction
- Linezolid — MAO inhibitory properties
- Meperidine — serotonin syndrome risk
- Severe renal impairment — reduced clearance
- Severe hepatic impairment — reduced metabolism
Drug Interactions Requiring Washout
| Drug | Washout Period Before MB |
|---|---|
| Fluoxetine (Prozac) | 5 weeks |
| Sertraline (Zoloft) | 2 weeks |
| Paroxetine (Paxil) | 2 weeks |
| Phenelzine (Nardil) | 2 weeks |
| Tranylcypromine (Parnate) | 2 weeks |
| Rasagiline (Azilect) | 2 weeks |
| Selegiline (Eldepryl) | — |
Swipe table →
Approaches Reported in the Literature
| Side Effect | Likely Cause | Management |
|---|---|---|
| Blue/green urine | Normal MB metabolism | Hydrate well |
| Blue staining mouth/teeth | Temporary, harmless | Rinse mouth after sublingual |
| Nausea | GI irritation | Studies administered; reduce dose |
| Headache | Vasodilation / dehydration | Hydrate; reduce dose |
| Jitteriness / anxiety | Stimulant effect | Reduce dose; take morning only |
| Insomnia | CNS stimulation | Avoid evening dosing |
Swipe table →
Less Common / Serious
| Side Effect | Likely Cause | Action |
|---|---|---|
| Hypotension | Vasodilatory effect at higher doses | Reduce dose; discontinue |
| Hemolysis | G6PD deficiency | Stop immediately; seek care |
| Serotonin syndrome | Stacking with serotonergics | Emergency — seek care |
| Anaphylaxis | Allergic reaction | Emergency — seek care |
| Chest pain / cardiac | High dose / underlying cardiac disease | Stop; seek care |
Swipe table →
Elderly
- Slower titration
- Monitor for hypotension and confusion
Cardiovascular Disease
- Use caution; MB can affect blood pressure
- Avoid high doses
- Physician consultation recommended
Cognitive Decline / Neurodegeneration
- Most evidence-supported use case (Alzheimer's, Parkinson's)
- May combine with red light therapy for synergistic effect
Rationale for Cycling
- Prevents receptor/sensitivity downregulation
- Reduces cumulative unknown risk
- Allows assessment of continued benefit
Uses
Weeks 1–4: On (5 days/week)
Weeks 5–6: Off
Weeks 7–10: On (3–4 days/week)
Weeks 11–12: Off
... repeat with assessment
Long-Term Safety Data
- Historical use since 1891 (anthelmintic, malaria, methemoglobinemia)
- No strong signals for cumulative toxicity at low doses
- Cancer genotoxicity: Some in vitro concern (DNA intercalation); not confirmed in humans
- Decision: Individual risk/benefit assessment; not a strong contraindication but monitor
Approved Formulation Updates
- PROVAYBLUE® (methylene blue) FDA prescribing information, revised January 2024: Updated labeling reflects methemoglobinemia indications in pediatric and adult populations. Remains the only FDA-approved injectable MB; off-label oral low-dose cognitive use is distinct from this approved product.
- Source: FDA prescribing information, Jan 2024 (cited in WebMD ingredient monograph, accessed 2025).
Phase 2 Alzheimer's / Healthy-Aging Trial Results Posted (2024)
- ClinicalTrials.gov NCT02380573 — UT Health San Antonio: Phase 2 trial of low-dose MB in healthy aging, mild cognitive impairment, and Alzheimer's disease. Results first posted September 2024 (study completion 2024-08 verification). fMRI outcome measures were used to evaluate sustained-attention and short-term memory brain activity. Trial is one of the few registered, registered-outcome human cognitive MB studies.
- Source: https://clinicaltrials.gov/study/NCT02380573
COVID-19 ARDS RCT (2025)
- Sanei et al. 2025 — MB in COVID-19 ARDS RCT (Naunyn Schmiedebergs Arch Pharmacol 398(2):1915–1924): Randomized clinical trial of IV methylene blue in hospitalized COVID-19 ARDS patients. Results reported in 2025; outcomes published as part of the broader MB-in-critical-illness literature. Adds to evidence that MB's redox-modulating activity may affect oxygenation parameters in critical illness without established mortality benefit.
- Source: Cited in WebMD monograph 2025.
PTSD Extinction-Learning Trial (Foundational Context)
- Zoellner et al. 2017 (J Clin Psychiatry 78:e782–9, PMID): RCT combining brief daily imaginal exposure with MB for PTSD — MB + exposure enhanced extinction learning vs. exposure + placebo. This remains the canonical PTSD-MB RCT and is the highest-quality signal in the psychiatric literature. Cited in 2024 reviews as the lead evidence for cognitive/psychiatric MB applications.
Safety Synthesis (2024 Update)
- Healthspan 2025 review and other 2024–2025 safety syntheses converge on: pharmaceutical-grade MB at 0.5–4 mg/kg is safe in adults without G6PD deficiency or serotonergic co-medication. Industrial-grade or aquarium MB is explicitly unsafe for internal use. Confirmed serotonin-syndrome risk at higher doses in patients on SSRIs/SNRIs/MAOIs/TCAs remains the dominant contraindication.
What to Buy
| Criteria | Requirement |
|---|---|
| Grade | USP pharmaceutical grade (for internal use) |
| Form | 1% solution in amber glass |
| Purity | Certificate of Analysis available |
| Supplier | Reputable lab/chems supplier (not industrial dye) |
| Additives | No unnecessary fillers, no heavy metals |
Swipe table →
Red Flags
- Industrial dye grade (for external/microscopy use only)
- Powder form (hard to dose accurately at mg quantities)
- No third-party testing / COA
- Seller with no verifiable reputation
Synergistic
| Combination | Rationale |
|---|---|
| Overview - Photobiomodulation (red/NIR light) | Same mitochondrial electron transport chain target; complementary mechanisms |
| NAD+ and Sirtuin Activators | ATP + NAD+ both support mitochondrial function |
| CoQ10 (Ubiquinol) | Electron transport chain support at Complex II |
| PQQ | Mitochondrial biogenesis (new mitochondria formation) |
| B-complex vitamins | Cofactors for energy metabolism |
Swipe table →
Avoid Combining
| Combination | Reason |
|---|---|
| High-dose SSRIs/SNRIs | Serotonin syndrome risk (at higher MB doses) |
| MAO inhibitors | Additive MAO inhibition → hypertensive crisis |
| 5-HTP / tryptophan | Serotonin precursor stacking risk |
| Lithium (mood stabilizer) | Unknown interaction; be cautious |
Swipe table →
What studies and practitioners report
Amounts as reported in the cited sources: trial doses with the population studied, and practitioner-reported ranges marked as such. Not medical advice.
- Trial 195 mg/day · Methylene blue, add-on to lamotrigine adults with bipolar disorder, crossover PMID 27284082
10Connections
11Sources
- PubMed 20731659PubMed 20731659
- PubMed 27351678PubMed 27351678
- PubMed 26961091PubMed 26961091
- NCT02380573NCT02380573
- NCT03446001NCT03446001
- PubMed 36281683PubMed 36281683
- PubMed 25079810PubMed 25079810
12Entry history
Latest content update.
Folded in 1 earlier page: methylene-blue-research-and-safety.
Heretic informs and never prescribes. Where amounts appear, they describe what published studies used. Talk to a qualified clinician before acting on anything here.